Zhang Yumin, Saylor Melissa, Wen Shenhua, Silva Matthew D, Rolfe Mark, Bolen Joseph, Muir Craig, Reimer Corinne, Chandra Sudeep
Department of Imaging Sciences/Platform Technology, Millennium Pharmaceuticals, Inc., 45 Sidney St., Cambridge, MA, 02139, USA.
Mol Imaging Biol. 2006 Sep-Oct;8(5):300-8. doi: 10.1007/s11307-006-0052-5.
The aim of this study was to validate quantitative metabolic response of tumors to a treatment measured by longitudinal 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) micro positron emission tomography (microPET) as a robust tool for preclinical evaluation of new anticancer agents.
Severe combined immunodeficiency mice with CWR22 xenografts were intravenously treated with bortezomib (Velcade) at 0.8 mg/kg on days 0, 3, 7, 10, and 14 and imaged with FDG microPET before, during and after treatment. Quantitative indices of tumor FDG uptake were developed.
FDG microPET images successfully revealed the gradual reduction of tumor FDG uptake on day 4 onward despite no absolute tumor shrinkage. The standardized uptake values of FDG in tumors was reduced to 43% of the baseline values. Using the total tumor FDG uptake as the viable tumor burden, we found 86% tumor inhibition, compared to a 55% tumor growth inhibition in tumor volume measurement.
FDG microPET imaging can provide an additional dimension of the efficacy of anticancer therapies that may otherwise be underestimated by tumor volume measurement.
本研究旨在验证通过纵向2-脱氧-2-[(18)F]氟-D-葡萄糖（FDG）微型正电子发射断层扫描（microPET）测量的肿瘤对治疗的定量代谢反应，作为临床前评估新型抗癌药物的可靠工具。
将携带CWR22异种移植瘤的严重联合免疫缺陷小鼠在第0、3、7、10和14天静脉注射硼替佐米（万珂），剂量为0.8mg/kg，并在治疗前、治疗期间和治疗后用FDG microPET成像。制定了肿瘤FDG摄取的定量指标。
尽管肿瘤没有绝对缩小，但FDG microPET图像成功显示从第4天起肿瘤FDG摄取逐渐减少。肿瘤中FDG的标准化摄取值降至基线值的43%。以肿瘤总的FDG摄取作为存活肿瘤负荷，我们发现肿瘤抑制率为86%，而肿瘤体积测量的肿瘤生长抑制率为55%。
FDG microPET成像可以提供抗癌治疗疗效的一个额外维度，否则可能会被肿瘤体积测量低估。
